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Murine Cytomegalovirus Protein pM92 Is a Conserved Regulator of
Viral Late Gene Expression
Travis J. Chapa,a Yi-Cheih Perng,a Anthony R. French,b Dong Yua
‹Department of Molecular Microbiology,a and Division of Pediatric Rheumatology, Department of Pediatrics,b Washington University School of Medicine, St. Louis,
Missouri, USA
In this study, we report that murine cytomegalovirus (MCMV) protein pM92 regulates viral late gene expression during virus
infection. Previously, we have shown that MCMV protein pM79 and its human cytomegalovirus (HCMV) homologue pUL79 are
required for late viral gene transcription. Identification of additional factors involved is critical to dissecting the mechanism of
this regulation. We show here that pM92 accumulated abundantly at late times of infection in a DNA synthesis-dependent man-
ner and localized to nuclear viral replication compartments. To investigate the role of pM92, we constructed a recombinant virus
SMin92, in which pM92 expression was disrupted by an insertional/frameshift mutation. During infection, SMin92 accumulated
representative viral immediate-early gene products, early gene products, and viral DNA sufficiently but had severe reduction in
the accumulation of late gene products and was thus unable to produce infectious progeny. Coimmunoprecipitation andmass
spectrometry analysis revealed an interaction between pM92 and pM79, as well as between their HCMV homologues pUL92 and
pUL79. Importantly, we showed that the growth defect of pUL92-deficient HCMV could be rescued in trans by pM92. This study
indicates that pM92 is an additional viral regulator of late gene expression, that these regulators (represented by pM92 and
pM79) may need to complex with each other for their activity, and that pM92 and pUL92 share a conserved function in CMV
infection. pM92 represents a potential new target for therapeutic intervention in CMV disease, and a gateway into studying a
largely uncharted viral process that is critical to the viral life cycle.
Human cytomegalovirus (HCMV), a prototypical member ofthe betaherpesvirus subfamily, is a ubiquitous pathogen lim-
ited to the human host (1). After the resolution of acute infection,
HCMV establishes a persistent, life-long infection characterized
by alternate stages of virus production and latency (1). In immu-
nocompetent hosts, the infection is typically asymptomatic. How-
ever, in immunocompromised hosts, lytic infection, during both
primary infection and reactivation from latency, can cause signif-
icant morbidity and mortality (1, 2). HCMV is the leading viral
cause of birth defects, such as deafness and mental retardation, in
perinatally infected infants (3, 4). It is a major cause of retinitis
and blindness in AIDS patients (2). It is a common source of
infectious complications in transplant recipients and cancer pa-
tients (5). Emerging evidence also provides a possible association
of HCMV infection with cardiovascular disease and proliferative
diseases such as cancer (6, 7). Currently there is no vaccine to this
virus, and antiviral therapies are limited by poor toxicity scores,
low availability, and emergence of resistant viruses (8). Under-
standing the role of viral genes in lytic infection is paramount and
will yield novel targets for antiviral therapies.
Murine CMV (MCMV) is the homologue of HCMV and
model of choice to study CMV biology and pathogenesis. It shares
conserved features with HCMV with regard to virion structure,
genome organization, gene expression, tissue tropism, and clinical
manifestations (9–12). Many genes of MCMV are conserved in
HCMV, and its ability to infect mice provides a tractable small
animal model to investigate virus infection in vivo. The use of
MCMV to explore conserved viral genes will shed light on the
roles of their counterparts in the replication and pathogenesis of
HCMV.
The lytic replication cycles of herpesviruses are characterized
by highly ordered cascades of gene expression, which can be se-
quentially divided into immediate-early (IE), early (E), and late
(L) phases (1). The expression of IE genes only requires cellular
factors and viral proteins associated with incoming virions. IE
proteins transactivate the expression of early genes that are re-
quired for viral DNA synthesis. Many of the early proteins localize
to viral nuclear replication compartments, where viral DNA syn-
thesis, late gene transcription, and viral genome encapsidation
take place (1). After viral DNA synthesis, late genes, many of
which encode structural proteins, are expressed to allow virion
assembly, maturation, and egress. It is also worth noting that some
genes have both early and late properties; their transcriptions start
prior to viral DNA synthesis, but the accumulation of their tran-
scripts is enhanced considerably after DNA synthesis.
Although the regulation of IE and E gene expression has been
studied extensively, less is known regarding the regulation of late
gene expression during CMV infection. Previously, we have
shown that MCMV protein pM79 is dispensable for viral DNA
synthesis but is a key regulator of late gene transcription during
MCMV infection (13). pM79 is conserved in both beta- and gam-
maherpesviruses, and its homologues in HCMV (pUL79) and
MHV68 (ORF18) have been shown to play similar roles during
virus infection (14–16). Identifying additional viral regulatory
factors in late gene expression will be critical to understand this
process. In the present study, we report that pM92 is another key
regulator of MCMV late gene transcription. Like pM79, pM92 is
also conserved in both beta- and gammaherpesviruses. Its homo-
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logues include pUL92 of HCMV, ORF31 of MHV68, and U63 of
HHV-6. However, the role of pM92 during MCMV infection has
not been defined, even though genome-wide mutagenesis analy-
ses have previously shown that both MHV68 ORF31 and HCMV
pUL92 are essential for lytic virus replication (17–19). Here, we
create a pM92-deficient MCMV mutant virus and show that, in
the absence of pM92, MCMV is capable of synthesizing its DNA at
wild-type levels but unable to efficiently produce late gene prod-
ucts. The M92 gene products abundantly accumulate at 20 h
postinfection (hpi) and localize to nuclear replication compart-
ments. We also provide evidence that pM92 interacts with pM79
during virus infection and that their HCMV homologues pUL92
and pUL79 interact as well. These results support the role of pM92
as a key regulator of viral late transcription and suggest that pM92
and pM79 are part of a multicomponent regulatory complex con-
trolling late transcription. Finally, we demonstrate the functional
conservation between MCMV pM92 and HCMV pUL92 by res-
cuing the growth defect of pUL92-deficient HCMV virus with
pM92 expression in trans. pM79 and pM92 offer attractive targets
for novel antivirals, and MCMV provides a powerful system to
dissect the regulatory mechanism of CMV late gene transcription,
as well as to test antivirals targeting steps other than viral DNA
synthesis. (In an accompanying paper, E. S. Mocarski and S.
Omoto [20] discuss the particular role of HCMV-encoded UL92
as a key regulator of late viral gene expression.)
MATERIALS AND METHODS
Plasmids, antibodies, and chemicals. pYD-C433, pYD-C569, pYD-
C245, and pYD-C618 were retroviral vectors derived from pRetro-EBNA
(21). pYD-C433 and pYD-C569 contained the C-terminally hemaggluti-
nin (HA)-tagged M38 and M79 coding sequences, respectively. pYD-
C245 expressed the red fluorescent protein (DsRed) (22) from an internal
ribosome entry site (IRES). pYD-C618 was derived from pYD-C245 and
carried the N-terminally 1FLAG-tagged M92 coding sequence that was
expressed together with DsRed as a bicistronic transcript. pYD-C755 (a
gift from Roger Everett, University of Glasgow Center for Viral Research),
pYD-C678, and pYD-C780 were pLKO.1-based lentiviral expression vec-
tors that carried a puromycin resistance marker (23, 24). Both pYD-C780
and pYD-C678 were derived from pYD-C755, and they carried the C-ter-
minally 3FLAG-tagged M92 and UL92 coding sequences, respectively.
pYD-C191 carried a kanamycin selection cassette bracketed by two Flp
recognition target (FRT) sites. pYD-C630 was derived from pGalK (25)
and carried a FRT-bracketed GalK/kanamycin dual selection cassette
(26). pYD-C746 was derived from pYD-C630, where a 3FLAG sequence
preceded the FRT-bracketed selection cassette.
The primary antibodies included: anti-actin (clone AC15; Abcam),
anti-FLAG polyclonal rabbit antibody (F7425) and monoclonal mouse
antibody (F1804) (Sigma), rat anti-HA (11867423001; Roche), anti-
MCMV IE1 (CROMA101) and E1 (CROMA103) (generous gifts from
Stipan Jonjic, University of Rijeka, Rijeka, Croatia), and anti-MCMV M44
(3B9.22A) and gB (2E8.21A) (generous gifts from Anthony Scalzo, Uni-
versity of Western Australia). The secondary antibodies used for immu-
noblotting were horseradish peroxidase (HRP)-conjugated goat anti-
mouse IgG, goat anti-rabbit IgG, and goat anti-rat IgG (Jackson
Laboratory). The secondary antibodies used for immunofluorescence
were Alexa Fluor 594-conjugated goat anti-mouse IgG and Alexa Fluor
488-conjugated goat anti-rabbit IgG (Invitrogen/Molecular Probes).
Other chemicals used in the present study included phosphonoacetic
acid (PAA) (284270-10G; Sigma-Aldrich), L-()-arabinose (A3256-25G;
Sigma-Aldrich), TO-PRO3 iodide (T3605; Invitrogen), Dynabeads
(Novex, Life Technologies), benzonase (Novagen, Fisher Scientific), and 4
to 12% gradient polyacrylamide NuPAGE gels (Novex, Life Technolo-
gies).
Cells and viruses. Mouse embryonic fibroblast 10.1 cells (MEF10.1)
(27), human embryonic lung fibroblasts (MRC5) (28, 29), and human
foreskin fibroblasts (HFF) were propagated in Dulbecco modified Eagle
medium supplemented with 10% fetal bovine serum, nonessential amino
acids, 1 mM sodium pyruvate, and 100 U of penicillin-streptomycin/ml.
Cells were maintained at 37°C and 5% CO2 in a humidified atmosphere.
To create cell lines stably expressing N-terminally 1FLAG-tagged pM92
(10.1-flagM92), MEF10.1 cells were transduced three times with pYD-
C618-derived retrovirus and allowed to recover for 48 h. DsRed-positive
cells were cloned by limiting dilution. Clonal cell lines were tested for their
ability to produce virus upon transfection with the mutant MCMV bac-
terial artificial chromosome (BAC) pSMin92 (see below). The cell line
yielding the highest titer at 5 days posttransfection was used in this study.
To create cells expressing C-terminally 3FLAG-tagged pM92 (MRC5-
M92flag) or pUL92 (MRC5-UL92flag), MRC5 cells were transduced with
lentivirus reconstituted from pYD-C780 or C678, respectively, and al-
lowed to recover for 48 h (30). To create cells containing the vector control
(MRC5-vector), MRC5 cells were transduced with pYD-C755-derived
vector lentivirus. Transduced cells were then selected with 1 g of puro-
mycin/ml and maintained with 0.5 g of puromycin/ml.
To reconstitute recombinant MCMV or HCMV viruses, confluent
MEF10.1 or MRC5 cells were electroporated with corresponding MCMV
or HCMV BAC DNA (see below), respectively. Recombinant MCMV
SMgfp and SMflag92 were reconstituted in MEF10.1 cells. SMin92 was
reconstituted in 10.1-flagM92 cells. To reconstitute recombinant HCMV,
BAC-HCMV DNA, pp71-expression plasmid, and G403-expression plas-
mid were cotransfected into MRC5-UL92flag cells by electroporation
(31). Cells were plated on a 10-cm plate, the medium was changed at 24 h
posttransfection, and virus was harvested by collecting cell-free culture
medium after the entire monolayer of cells was lysed. Alternatively, virus
stocks were produced by collecting cell-free supernatant from infected
culture at a multiplicity of infection (MOI) of 0.001. Virus titers were
determined in duplicate by a 50% tissue culture infectious dose (TCID50)
assay in the appropriate cell type. In experiments where comparative anal-
ysis was performed between SMin92 or ADinUL92 with other recombi-
nant viruses, titers for all of the viruses were determined in 10.1-flagM92
or MRC5-UL92flag cells, respectively.
BAC recombineering. Recombinant BAC clones in the present study
were created by using a linear recombination-based BAC recombineering
protocol that we have previously established (26). Recombination was
carried out in E. coli strain SW105 that harbored either the MCMV or
HCMV BAC clone and expressed an arabinose-inducible Flippase gene for
transient expression of Flp recombinase (25).
Recombinant MCMV BAC clones were derived from the parental
clone pSM3fr that carried a full-length genome of the MCMV Smith
strain (32). pSMgfp, used as the wild-type clone in this study, contained
the green fluorescent protein (GFP) expression cassette at the C terminus
of the IE2 loci, which has been shown to be dispensable for MCMV infec-
tion in vivo and in vitro (33–35). The clone pSMin92 carried a frameshift
mutation in the MCMV gene M92 (Fig. 1A). To construct pSMin92, the
FRT-bracketed GalK/kanamycin cassette was PCR amplified from pYD-
C630 and recombined into pSMgfp at nucleotide (nt) 358 of the M92
coding sequence. The selection cassette was then removed by arabinose
induction of Flp recombinase and subsequent Flp-FRT recombination
(26), leaving an 88-nt insert within M92 to create a frameshift mutation.
The clone pSMflag92 contained an N-terminally 3FLAG-tagged M92
coding sequence (Fig. 1A). To construct pSMflag92, a fragment contain-
ing the FRT-bracketed GalK/kanamycin selection cassette preceded by a
3FLAG sequence was PCR amplified from pYD-C746 and recombined
into the N terminus of the M92 coding sequence of pSMgfp. The selection
cassette was subsequently removed by Flp-FRT recombination, resulting
in the 3FLAG fused in frame with the M92 coding sequence. Recombi-
nant HCMV BAC clones were derived from the parental clone pAD/Cre
that carried the full-length genome of HCMV strain AD169 (31). pADgfp,
used as the wild-type clone here, had a green fluorescent protein (GFP)
Chapa et al.
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gene in place of the viral US4-US6 region (31, 36). pADflagUL79 was
similar to pADgfp except that the 5= terminus of UL79 coding sequence
was tagged with 3FLAG. The clone pADinUL92 was created in a similar
manner to that of pSMin92, except that the insertion replaced nt 125 to
406 of the UL92 coding sequence carried in pADgfp. All of the BAC clones
were validated by restriction digestion, PCR analysis, and direct sequenc-
ing, as previously described (37).
Viral growth analysis. MEF10.1 or MRC5 cells were seeded in 12-well
plates overnight to produce a confluent monolayer. Cells were inoculated
with recombinant viruses for 1 h at an MOI of 2 for single step or 0.001 for
multistep growth analysis. The inoculum was removed, the infected
monolayer was rinsed with phosphate-buffered saline (PBS), and fresh
medium was replenished. At various times postinfection, cell-free virus
was collected in duplicate by harvesting medium from infected cultures.
Cell-associated virus was collected by rinsing infected cells once with PBS
and scraping cells into fresh medium. Cells were lysed by one freeze-thaw
cycle, followed by sonication. Lysates were cleared of cell debris by low-
speed centrifugation, and supernatants were saved as cell-associated virus.
Virus titers were determined by TCID50 assay.
DNA and RNA analysis. Intracellular DNA was measured by quanti-
tative PCR (qPCR) as previously described (13). Briefly, cells were col-
lected in a lysis buffer (200 mM NaCl, 20 mM Tris [pH 8.0], 20 mM
EDTA, 0.2 mg of proteinase K/ml, 0.4% sodium dodecyl sulfate [SDS]),
and lysed by incubation at 55°C overnight. DNA was extracted with phe-
nol-chloroform and treated with RNase A (100 g/ml) at 37°C for 1 h.
Samples were extracted again with phenol-chloroform, precipitated with
ethanol, and resuspended in nuclease-free water (Ambion). Viral DNA
was quantified by qPCR using SYBR Advantage qPCR Premix (Clontech)
and a primer pair specific for the MCMV IE1 gene (13). Cellular DNA was
quantified by using a primer pair specific for the mouse actin gene (13). A
standard curve was generated using serially diluted pSMgfp BAC DNA or
cellular DNA and was used to calculate relative amounts of viral or cellular
DNA in a sample. The amount of viral DNA was normalized by dividing
IE1 equivalents over actin gene equivalents. The normalized amount of
viral DNA in SMgfp infected cells at 10 hpi was set at 1.
Intracellular RNA was determined by reverse transcription-coupled
qPCR (RT-qPCR) as previously described (13). Total RNA was extracted
by TRIzol reagent (Invitrogen) and treated with Turbo DNA-free reagents
(Ambion) to remove contaminating DNA. First-strand cDNA synthesis
was performed with a high-capacity cDNA reverse transcription kit using
random hexamer-primered total RNA (Applied Biosystems). Each sam-
ple also included a control without the addition of reverse transcriptase to
determine the level of residual contaminating DNA. cDNA was quantified
by using SYBR Advantage qPCR Premix (Clonetech) and primer pairs
specific for viral genes or cellular -actin (Table 1). A standard curve was
generated for each gene using serially diluted cDNA from infected cells
and was used to calculate the relative amount of a transcript in each sam-
ple. The amounts of viral transcript were normalized by dividing viral
transcript equivalents over actin equivalents. The normalized amount of
transcript during SMgfp infection at 10 hpi in the absence of PAA was set
to 1.
Protein analysis. Protein accumulation was analyzed by immuno-
blotting. Cells were washed, and lysates were collected in sodium dodecyl
sulfate (SDS)-containing sample buffer. Proteins were resolved by SDS-
FIG 1 pM92 is essential for MCMV replication in fibroblasts. (A) Diagram depicting the construction of MCMV BACs used in the present study by BAC
recombineering. To create pSMin92, an 88-nt insert was introduced (indicated by the black bar) at nt 358 of the M92 coding sequence, resulting in a frameshift
mutation. pSMflag92 was created by fusing a 3FLAG tag in frame at the N terminus of the M92 coding sequence (indicated by the shaded bar). (B) Growth of
SMin92 virus in MEF 10.1 cells expressing FLAG-tagged pM92 (10.1-flagM92). Left panels are fluorescent images of virus-driven GFP expression in MEF 10.1
cells or 10.1-flagM92 cells, both of which were transfected with pSMin92. Images were taken at 7 days posttransfection. Right panels are titers of cell free virus at
72 hpi from 10.1-flagM92 cells infected with either SMgfp or SMin92 at an MOI of 2. (C and D) Growth kinetic analysis of MCMV recombinant viruses used in
the present study. MEF 10.1 cells were infected with indicated viruses at an MOI of 2 (for single-step growth analysis) or 0.001 (for multistep growth analysis).
Cell-free and cell-associated viruses were collected at indicated times and titers were determined by TCID50 assay in 10.1-flagM92 cells. The detection limit of the
TCID50 is indicated by a dashed line.
CMV pM92/pUL92 Proteins Regulate Late Gene Expression
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containing polyacrylamide gel electrophoresis (PAGE) and transferred
onto a polyvinylidene difluoride membrane. Proteins of interest were de-
tected by hybridizing the membrane with specific primary antibodies,
followed by HRP-coupled secondary antibodies, and visualized by using
SuperSignal West Pico enhanced chemiluminescent (ECL) substrate
(Thermo Scientific).
Intracellular localization of proteins of interest was analyzed by using
an immunofluorescence assay. Cells were seeded onto coverslips 24 h
prior to infection. At 24 hpi, the cells were washed with PBS, fixed, per-
meabilized with methanol (20°C) for 10 min, and blocked with 5% fetal
bovine serum in PBS at room temperature for 1 h. Cells were incubated
with primary antibodies for 30 min at room temperature and subse-
quently labeled with secondary antibodies coupled to Alexa Fluor 488 or
Alexa Fluor 594 (Invitrogen-Molecular Probes). Cells were counter-
stained with TO-PRO3 and mounted on slides with Prolong Gold anti-
fade reagent (Invitrogen-Molecular Probes). Confocal microscopic im-
ages were captured by a Zeiss LSM510 Meta confocal laser scanning
microscope.
Protein interactions were analyzed by coimmunoprecipitation. For
MCMV, MEF 10.1 cells transiently expressing C-terminally HA tagged
M38 or M79 were infected with SMflag92 at an MOI of 2. Cells were
collected at 48 hpi and lysed by incubation with extraction buffer (50 mM
Tris [pH 8.0], 300 mM NaCl, 0.5% NP-40) for 15 min. In the meantime,
1 g of FLAG-antibody was conjugated to 25 l of Dynabeads (Novex,
Life Technologies) by incubation in conjugation buffer (0.02% Tween 20
in PBS [pH 7.2]) for 20 min at room temperature. Lysates were cleared by
centrifugation, the pellet of cellular debris was saved, and the supernatant
was incubated with FLAG antibody-conjugated Dynabeads in the pres-
ence of endonuclease Benzonase (800 U/ml) (that digested DNA and pre-
vented DNA-mediated, nonspecific interactions among DNA-binding
proteins). After an overnight incubation, beads were washed four times
with extraction buffer, and supernatant was saved as flowthrough.
Washed beads were mixed with NuPAGE LDS sample buffer (Invitrogen)
and boiled to elute FLAG-associated proteins. Pellets, flowthrough, and
eluted samples were analyzed by an SDS-PAGE gel, followed by immuno-
blotting. For HCMV, HFF cells were infected with ADgfp or ADflagUL79
(16) at an MOI of 3. Infected cells were collected and lysed at 72 hpi, and
immunoprecipitation was performed as described above. After elution,
the samples were resolved on an SDS-PAGE gel, and protein bands were
visualized by silver staining using a ProteoSilver Plus silver stain kit
(Sigma).
RESULTS
pM92 is essential forMCMVreplication in fibroblasts.The M92
open reading frame (ORF) is predicted to encode a gene product
of 231 amino acids (aa) and is a sequence homologue to the
HCMV ORF UL92 (202 aa). UL92 is essential for virus replication
during HCMV infection (19), but the importance of M92 in
MCMV infection in fibroblasts has not yet been established. To
investigate this, a frameshift mutation was introduced at nt 358 of
the predicted M92 ORF by BAC recombineering (13, 26), produc-
ing mutant BAC pSMin92 (Fig. 1A). This insertion is not expected
to interfere with the expression of neighboring genes, particularly
the 5=-terminally overlapping M93. Transfection of wild-type
pSMgfp BAC in MEF10.1 cells produced virus (termed SMgfp),
resulting in a complete cytopathic effect (CPE) of the monolayer
and full spread of the virus-driven GFP expression at 5 days post-
transfection, whereas transfection of pSMin92 failed to show any
sign of CPE even at 2 weeks posttransfection (Fig. 1B). However,
pM92-deficient virus (termed SMin92) was rapidly reconstituted
to wild-type levels from pSMin92 upon transfection into MEF
10.1 cell that stably expressed N-terminally 1FLAG-tagged
pM92 (10.1-flagM92). Thus, the defect of SMin92 is the direct
result of pM92 ablation.
To more precisely define the growth defect of SMin92, we per-
formed growth curve analyses to quantify the defect of the recom-
binant virus and validate the essentiality of pM92 (Fig. 1C).
SMin92 failed to produce detectable levels of cell-free or cell-as-
sociated progeny through the entire course of analysis, indicating
that pM92 is essential for MCMV replication at steps prior to virus
release.
pM92 is a 25-kDa protein that accumulates to high levels at
late times of infection. A thorough search of available nucleotide
and amino acid sequence databases failed to identify any signifi-
cant homology of pM92 to proteins with known function. To
acquire basic information and gain insights into the role of pM92,
we first characterized potential protein and transcript products
from this gene. Since no antibody was available for detecting the
M92 protein product, we created a recombinant MCMV BAC,
pSMflag92, in which the M92 coding sequence was tagged with
3FLAG at the N terminus (Fig. 1A). Transfection of pSMflag92
BAC in MEF 10.1 cells rapidly reconstituted recombinant virus,
termed SMflag92. Both single-step and multistep growth curve
analyses indicated that SMflag92 grew similarly to SMgfp (Fig.
1D), suggesting that the 3FLAG tag did not interfere with the
function of M92 or neighboring gene M91 (Fig. 1A). 3FLAG-
tagged pM92 (pflagM92) migrated at the expected size of 25 kDa,
became detectable at 24 hpi, and accumulated at more abundant
TABLE 1 Primers used in PCR analysis
Primer Sequence (5=–3=)
MCMV IE1 forward CAGGGTGGATCATGAAGCCT
MCMV IE1 reverse AGCGCATCGAAAGACAACG
MCMV M34 forward TACTCTGATCGCGAACAGCA
MCMV M34 reverse GCGTTGGTGGTTCGTGTCTG
MCMV M37 forward ATGACGGCGGTCCTCTCCAT
MCMV M37 reverse ACGTGTACGTCTTCCGTGCC
MCMV M45 forward GGAACTCCTTGGTCATGCGA
MCMV M45 reverse TTCCCCAAGTTCCCTAAGAG
MCMV M46 forward CTGAACCTATAGCGCAGGAC
MCMV M46 reverse ACTATAATAGCGATCGGCAG
MCMV M55 (gB) forward GCGATGTCCGAGTGTGTCAAG
MCMV M55 (gB) reverse CGACCAGCGGTCTCGAATAAC
MCMV M74 forward AGGAGGCTGTGACTTTGAAA
MCMV M74 reverse CTCATCAGCCGTTACTCGAG
MCMV M85 forward TTTCATGAGGAGCATGTTGC
MCMV M85 reverse CTGCATCTCGCTCTCCATGA
MCMV M92 forward AAACCCACGGAGAATGCGAT
MCMV M92 reverse ACGAACAGCTGACCTATGACGC
MCMV M96 forward TCGAGGCGTTCGGTCCTGAT
MCMV M96 reverse CGCATTCTCGGATACTCGCT
MCMV M102 forward AGACCAGTACGGCGATCCAG
MCMV M102 reverse AGCTTCCTGTAGGCGTGCGT
MCMV M112/113 (E1) forward GAATCCGAGGAGGAAGACGAT
MCMV M112/113 (E1) reverse GGTGAACGTTTGCTCGATCTC
MCMV M116 forward TCCTTGGTGGTGATGGCGGT
MCMV M116 reverse GCATCCCGTACCTGACCACA
Mouse actin forward GCTGTATTCCCCTCCATCGTG





a Primer used in PCR analysis of cellular DNA from pM92- or pUL92-expressing
MRC5 cells.
Chapa et al.
134 jvi.asm.org Journal of Virology
 o
n
 January 28, 2014 by W






levels at 48 hpi during SMflag92 infection (Fig. 2A). To profile its
transcription, we determined the accumulation of M92 transcript
by reverse transcription-coupled quantitative PCR analysis (RT-
qPCR). In agreement with its protein accumulation profile, M92
transcript levels were low at 10 hpi but increased 8-fold at 20 hpi
(Fig. 2B). Importantly, M92 transcription was dramatically re-
duced when viral DNA synthesis was inhibited by phosphono-
acetic acid (PAA) at 20 hpi (Fig. 2B). Therefore, M92 gene prod-
ucts accumulate abundantly in a viral DNA synthesis-dependent
manner at late times of infection.
pM92 localizes to viral nuclear replication compartments
during infection. To further characterize pM92, we next exam-
ined the intracellular localization of 3FLAG-tagged pM92 dur-
ing infection of SMflag92. Infected cells were fixed and permeab-
ilized with methanol, which also quenched GFP fluorescence, thus
allowing visualization of pM92 localization using Alexa Fluor 488-
conjugated mouse anti-flag antibody by indirect immunofluores-
cence. pM92 localized to the nuclei of infected cells, and in partic-
ular, it localized to subnuclear structures resembling those of
nuclear replication compartments (Fig. 2D). This led us to hy-
pothesize that pM92 localized to viral replication compartments
during infection. To test this, we compared intracellular localiza-
tion of 3FLAG-tagged pM92 to that of viral protein pM44 (i.e.,
the viral polymerase processivity factor and commonly used
marker for replication compartments) during infection of
SMflag92. Since the anti-pM44 antibody is of mouse origin, we
used a rabbit anti-FLAG antibody to costain pM92 in this exper-
iment. At 24 hpi, FLAG staining strongly colocalized with pM44 in
the nuclei of SMflag92-infected cells (Fig. 2C), indicating that the
majority of pM92 localizes within replication compartments. The
rabbit anti-FLAG antibody has been previously shown to have
high background staining (13). In this experiment, it also pro-
duced a diffuse, weak cytoplasmic staining, which likely repre-
sented nonspecific background since it was also present in SMgfp-
infected control cells. Collectively, we conclude that pM92 is a
nuclear protein that localizes to replication compartments during
MCMV infection.
pM92 is dispensable for viralDNAsynthesis but required for
efficient late gene expression.To define the function of pM92, we
first determined where it acted in the viral life cycle, hypothesizing
that pM92 might be required for viral DNA synthesis as it local-
ized to replication compartments (Fig. 2). However, qPCR analy-
sis showed that viral DNA accumulation over the course of
SMin92 infection was comparable to that during SMgfp infection
FIG 2 pM92 accumulates abundantly at late times of infection and localizes to viral nuclear replication compartments. (A) Accumulation of the M92 protein
product during MCMV infection. MEF 10.1 cells were infected with SMflag92 virus at an MOI of 2. Total cell lysates were harvested at indicated times
postinfection and analyzed by immunoblotting. The M92 protein was detected with the mouse anti-FLAG antibody, and actin was included as a loading control.
(B) Accumulation of the M92 transcript during MCMV infection. MEF 10.1 cells were infected with SMgfp at an MOI of 2 in the presence or absence of viral DNA
synthesis inhibitor PAA (200 g/ml). Total RNA was isolated at indicated times postinfection and the M92 transcript was measured by RT-qPCR analysis with
the primers listed in Table 1. The values were normalized to -actin, and the normalized amount of M92 transcript at 10 hpi in the absence of PAA was set to the
value of 1. (C and D) The M92 protein localizes to nuclear replication compartments during infection. MEF 10.1 cells were mock infected or infected with SMgfp
or SMflag92 at an MOI of 2. At 24 hpi, cells were permeabilized and fixed with methanol and stained with either rabbit polyclonal (C) or mouse monoclonal (D)
anti-FLAG antibody to detect the FLAG-tagged M92 protein (green). In panel C, cells were also stained with mouse antibody to pM44, which served as a marker
for replication compartments. Cells were counterstained with TO-PRO3 to visualize the nuclei. Scale bars, 20 m.
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(Fig. 3C). This result indicates that pM92 is not required for viral
DNA synthesis.
To test whether pM92 is required for late gene expression, a
viral event immediately downstream of viral DNA synthesis, we
next examined the accumulation of immediate-early protein IE1,
early protein E1 (M112/113), and late protein gB (M55) during
SMin92 infection by immunoblot analysis. Compared to wild-
type control SMgfp, SMin92 appeared to have two defects during
infection. The first was a modest decrease in the accumulation of
E1 protein at early times of infection. The second, and more strik-
ing defect, was that accumulation of late protein gB was reduced to
undetectable levels in SMin92 infection (Fig. 3A). Early genes pri-
marily function prior to viral DNA synthesis. Since no measurable
defect was observed in DNA synthesis during SMin92 infection
(Fig. 3C), the modest decrease in E1 accumulation was unlikely
the main cause for the growth defect of SMin92. It is unclear why
SMin92 has this minor defect in early gene expression. It may be a
result of suboptimal complementation by the 10.1-flagM92 cells
used to produce the mutant virus. It is also reminiscent of a similar
observation reported for pM79-deficient virus (13). We therefore
hypothesized that the inability of SMin92 to replicate was likely
due to the failure to efficiently produce late proteins during infec-
tion.
To determine whether the defect was at the transcriptional
level, we measured the transcript accumulation of representative
immediate-early (IE1), early (E1), and late (M55) genes in the
presence or absence of pM92 during virus infection by RT-qPCR.
The expression kinetics of these genes was validated by treatment
with the DNA synthesis inhibitor PAA. As expected, both IE and
E1 gene expression was resistant to PAA, whereas late gene M55
expression was markedly sensitive to PAA (Fig. 3B). Importantly,
in the absence of pM92, IE1 and E1 transcripts accumulated at
wild-type levels, but the accumulation of late transcript M55 was
significantly reduced (Fig. 3B). Therefore, pM92 is required for
efficient transcript accumulation of late gene M55 during MCMV
infection.
This result led us to hypothesize that pM92 is a new member of
the viral late transcription regulators, which includes recently re-
ported pM79 (13). To test whether pM92 had a global regulatory
role in viral late transcription, we examined transcript accumula-
tion of multiple early genes (M34, M37, M45, and M102) and late
genes (M46, M74, M85, M96, and M116) during SMin92 infec-
tion. Transcription of early genes was independent of viral DNA
synthesis and consequently only modestly affected by PAA treat-
ment (2-fold), a finding consistent with previous reports (Fig.
4A) (13). Importantly, the effect of pM92 mutation on early gene
transcription was as modest as PAA treatment, indicating that
pM92 is not required for efficient early gene expression. In stark
contrast, late gene transcription was dependent on viral DNA syn-
thesis and therefore significantly sensitive to PAA (Fig. 4B). Im-
portantly, transcription of these genes was also significantly re-
duced during SMin92 infection. It was also noted that
FIG 3 pM92 is dispensable for viral DNA synthesis but is required for efficient accumulation of M55 late gene products during infection. (A) Accumulation of
representative viral proteins during pM92-defcient virus infection. MEF 10.1 cells were infected with SMgfp or SMin92 at an MOI of 2. Cell lysates were harvested
at indicated times and analyzed by immunoblotting. (B) Accumulation of viral transcripts during pM92-deficient virus infection. MEF 10.1 cells were infected
with SMgfp in the presence or absence of viral DNA synthesis inhibitor PAA (200 g/ml) or with SMin92 at an MOI of 2. At 10 and 20 hpi, total RNA was
harvested, and specific transcripts were quantified by RT-qPCR analysis using the primers listed in Table 1. The values were normalized to -actin, and the
normalized amount of transcript during SMgfp infection at 10 hpi in the absence of PAA was set to the value of 1. (C) Accumulation of viral DNA during
pM92-deficient virus infection. MEF 10.1 cells were infected as described in panel A, total DNA was isolated from infected cells at the indicated times, and viral
DNA synthesis was analyzed by qPCR. The values were normalized to -actin, and the quantity of DNA during SMgfp infection at 10 hpi was set to 1.
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transcription of individual genes showed various levels of depen-
dency on pM92 relative to that on viral DNA synthesis. Reduction
in M116 and M46 transcriptions in the absence of pM92 was com-
parable to that with PAA treatment, whereas the reduction in M96
and M74 transcription in the absence of pM92 was less pro-
nounced. This is reminiscent of the previous report that different
late gene transcriptions have different dependency on the viral late
transcription regulator pM79 (13). Our results indicate that pM92
plays an important role in regulating late gene transcription dur-
ing MCMV infection.
CMV UL92/M92 proteins interact with UL79/M79 proteins
during infection. We have previously found that MCMV protein
pM79 regulates viral late transcription (13). Since we showed here
that pM92 also played a critical role in late gene expression, we
hypothesized that these two proteins might interact and form a
functional complex to exert this regulatory activity. To test this,
we created a retroviral vector expressing the C-terminally HA-
tagged M79 ORF (pM79ha) or MCMV M38 ORF as a control
(pM38ha) and transfected it into MEF10.1 cells to generate ex-
pression cells. Transfected cells were subsequently infected with
SMflag92, and cell lysates were collected at 48 hpi. FLAG-tagged
pM92 complexes were immunoprecipitated with the mouse
anti-FLAG antibody and analyzed by immunoblotting (Fig. 5A).
pM79ha coimmunoprecipitated with pflagM92, indicated by its
relative abundance in the eluted sample compared to that in the
flowthrough sample. The interaction was specific, since the con-
trol pM38ha, a protein not thought to be involved in late gene
regulation, was only detected in the flowthrough wash but not in
the eluted sample. These results suggest that pM79 and pM92
interact during MCMV infection.
Since MCMV M79 and HCMV UL79 play a similar role in late
gene expression during infection (13, 16), we wanted to determine
whether pUL79 also interacted with pUL92, the HCMV homo-
logue of pM92, during infection. To test this, we infected HFF cells
with recombinant HCMV expressing N-terminally 3FLAG-
tagged pUL79 (ADflagUL79) or wild-type HCMV (ADgfp). Cell
lysates were collected at 72 hpi and coimmunoprecipitated with
anti-FLAG antibody. Immunoprecipitants were resolved by SDS-
PAGE, followed by silver staining analysis. Protein bands present
in ADflagUL79-infected samples but absent in ADgfp-infected
control samples were extracted. As the control, gel bands from
ADgfp-infected samples with migrating positions corresponding
to those of ADflagUL79-specific protein bands were also extracted
(Fig. 5B). The protein identities in both samples were determined
by mass spectrometry analysis. Proteins that were only present in
ADflagUL79-infected samples but not in ADgfp-infected samples
were considered as specifically binding to pUL79. pUL92 was
among the pUL79-associated viral proteins identified by this anal-
ysis (Fig. 5B). Taken together, our results suggest that two viral
regulators of late gene expression, pM79 and pM92, interact dur-
ing MCMV infection, and that this interaction is conserved be-
tween MCMV and HCMV.
pM92 trans-complements the growth of pUL92-deficient
HCMV virus. MCMV pM92 and HCMV pUL92 share 50% iden-
tity and 71% similarity at the amino acid level and notably pM92
has an additional 30 aa at the N terminus (Fig. 6A). Since pM92
and pUL92 share significant sequence homology and a similar
interaction partner (i.e., pM79 and pUL79, respectively), we hy-
pothesized that pM92 and pUL92 were functional homologues.
To test this, we first constructed a pUL92-deficient HCMV recom-
binant BAC clone, pADinUL92, by FLP/FRT-mediated BAC re-
combineering (Fig. 6B). pADinUL92 carried an 88-nt insertion at
nt 124 of the UL92 ORF to replace a 282-nt segment of the coding
sequence. The location of the mutation was expected not to inter-
fere with expression of neighboring genes, namely, the overlap-
ping 3= terminus of UL91 or 5= terminus of UL93. Transfection of
pADinUL92 BAC into MRC5 cells failed to produce any infectious
virus even after 4 weeks of incubation, whereas cells transfected
with the wild-type BAC pADgfp readily developed complete CPE
and a full spread of virus-driven GFP expression. This was in ac-
FIG 4 pM92 is required for efficient accumulation of a panel of late transcripts. MEF 10.1 cells were infected with SMgfp in the presence or absence of viral DNA
synthesis inhibitor PAA (200 g/ml) or with SMin92 at an MOI of 2. At the indicated times, total RNA was harvested and then representative early transcripts
(A) and late transcripts (B) were quantified by RT-qPCR analysis using the primers listed in Table 1. The y axis represents relative viral transcript (fold increase).
The values were normalized to -actin, and the normalized amount of transcript during SMgfp infection at 10 hpi in the absence of PAA was set to 1.
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cordance with previous reports that UL92 is essential for HCMV
viral replication in fibroblasts (19). To reconstitute pUL92-defi-
cient virus, we constructed a lentivirus carrying the C-terminally
3FLAG-tagged UL92 ORF and subsequently generated pUL92
expressing cells by lentiviral transduction (MRC5-UL92flag).
Transfection of pADinUL92 into MRC5-UL92flag cells could now
reconstitute infectious progeny virus, ADinUL92, with wild-type
titers. Therefore, pUL92 is essential for HCMV replication, and
the growth defect of the HCMV recombinant virus ADinUL92
was due to the disruption of pUL92 expression.
To determine whether pM92 is the functional homologue of
pUL92, we tested whether pM92 expression could trans-comple-
ment the growth of pUL92-deficient virus. We created a lentivirus
containing the C-terminally 3FLAG-tagged M92 ORF and sub-
sequently generated pM92-expressing MRC5 cells by lentiviral
transduction (MRC5-M92flag). We then infected MRC5 cells ex-
pressing pUL92 (MRC5-UL92flag), pM92 (MRC5-M92flag), or
empty vector (MRC5-vector) with ADinUL92 at an MOI of 0.001
and determined the titer of the cell free virus produced at 14 dpi.
Both infected MRC5-UL92flag and MRC5-M92flag showed
spread of the pUL92-deficient virus at 14 dpi, whereas MRC5-
vector showed little sign of CPE (Fig. 6C). Analysis of the final
titers of infected culture supernatants indicated that pM92 could
complement ADinUL92 to titers similar to that by pUL92 (Fig.
6D). PCR analysis of genomic DNA from MRC5-UL92flag and
pM92 MRC5-M92flag confirmed that there was no cross-contam-
ination of these two cell types (Fig. 6E). Therefore, pM92 and
pUL92 have a conserved function during CMV infection.
DISCUSSION
The expression of late genes is an essential step for CMV to com-
plete its lytic infection cycle. Key viral factors required in this
process could be attractive targets for antiviral strategies to pre-
vent CMV infection and disease. In the present study, we deter-
mined the role of MCMV protein pM92 during virus infection.
pM92 accumulated at late times and localized to nuclear replica-
tion compartments during infection (Fig. 2). When pM92 was
abolished, the accumulation of early gene products and viral DNA
was minimally affected, but the accumulation of late gene prod-
ucts was markedly reduced (Fig. 3 and 4). As a result, the mutant
virus failed to complete the infection cycle to produce progeny
virus (Fig. 1). Therefore, pM92 is a novel regulator of viral late
gene expression and thus plays an essential role in the MCMV lytic
infection cycle.
Our study provides additional evidence that the regulatory
mechanism of viral late gene expression is conserved between
MCMV and HCMV. We have previously shown that MCMV pro-
tein pM79 and its HCMV homologue pUL79 regulate viral late
gene expression (13, 16). In the present study, we demonstrated
that pM92 interacted with pM79 during MCMV infection; like-
wise, pUL92 could interact with pUL79 during HCMV infection
(Fig. 5). This suggests that during betaherpesvirus infection, a
complex containing similar components of virus-encoded factors
forms to promote late gene expression. How this complex func-
tions and what additional protein components are in this complex
remain important questions. Furthermore, we demonstrated that
viral protein pUL92, the HCMV homologue of pM92, was also
essential for virus infection (Fig. 6). Importantly, pM92 could
trans-complement the growth of pUL92-deficient HCMV recom-
binant virus (Fig. 6). These experiments do not specify whether
the compensation occurs at the transcriptional or translational
level during HCMV infection, and further work is required to
define the exact mechanism at play. Regardless, these findings
suggest a conserved function for pM92 homologues among beta-
herpesviruses.
Our study also provides additional evidence that viral DNA
synthesis is necessary but not sufficient to drive late viral gene
expression during herpesvirus infection. Inhibition of the viral
FIG 5 CMV UL92/M92 proteins interact with UL79/M79 proteins during infection. (A) MEF10.1 cells expressing either HA-tagged M79 (pM79ha) or
HA-tagged M38 (pM38ha) were infected with SMflag92 at an MOI of 2, and cell lysates were collected at 48 hpi. Cell lysates were separated into insoluble cell
debris (pellet, “P”) and supernatant by centrifugation. Supernatant was then immunoprecipitated with the mouse anti-FLAG antibody, washed, and eluted. Cell
debris (“P”), flowthrough fraction collected by wash (“FT”), and eluted fraction (“E”) were analyzed by immunoblotting with anti-FLAG and anti-HA
antibodies. (B) HFF cells were infected with wild-type (ADgfp) or FLAG-tagged UL79 recombinant HCMV virus (ADflagUL79) at an MOI of 3. Cell lysates were
prepared at 72 hpi and immunoprecipitated with an anti-FLAG antibody. In the top panel, immunoprecipitants were separated on a gradient polyacrylamide gel,
and protein bands were visualized by silver stain. Indicated is the protein band that contained pUL92 as identified by mass spectrometry. The bottom panel shows
the parameters of mass spectrometry analysis for identifying HCMV pUL92. Gel bands with the same migrating positions were extracted from both lanes of the
top panel and comparatively analyzed by mass spectrometry. pUL92 was identified only in the ADflagUL79 samples but not in the ADgfp sample. Superscript
letters: a, identities of remaining pUL79-binding proteins are included in a separate study; b, expectation value for peptide match. A lower value indicates a higher
likelihood of the interaction. Molecular mass markers (in kilodaltons) are also indicated.
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polymerase by PAA abolishes the accumulation of late transcripts
(38–41). This dependence on viral DNA synthesis has been linked
to the origin of lytic replication (oriLyt), since the oriLyt sequence
is required in cis for proper expression of late transcripts in many
herpesviruses (42–46). However, our previous data and the data
presented here demonstrate that viral gene expression at late times
of infection depends not only on viral DNA in cis but also on viral
factors such as pM92 and pM79 in trans (13). In the absence of
these viral factors, DNA synthesis kinetics were indistinguishable
from those of wild-type virus despite a defect in late transcript
accumulation. Therefore, pM92 does not function as a viral DNA
synthesis protein; rather, it specifically acts on gene expression at
late times of infection.
What is the mechanism of pM92 activity? It has been estab-
lished that herpesviral genomes associate with histones during
infection and require epigenetic regulation for gene expression
(47–53). One possible mechanism is that the pM92/pM79 com-
plex may activate late gene transcription by remodeling the chro-
matin structure of the viral genome. This could be accomplished
by recruiting chromatin-remodeling complexes to the late gene
loci, and rendering their promoters accessible for transcription.
Such activity has been observed for herpes simplex virus 1
FIG 6 pM92 trans-complements the growth of pUL92-deficient HCMV virus. (A) Coding sequence alignment of MCMV M92 with its homologues HCMV
UL92 and MHV68 ORF31. (B) Diagram depicting the construction of pUL92-deficient recombinant HCMV BAC, pADinUL92, by BAC recombineering.
pADinUL92 carried an 88-nt insertion (indicated by black bar) at nt 124 of the UL92 ORF to replace a 282-nt segment of the coding sequence. (C and D) Growth
of ADinUL92 virus in MRC5 cells expressing C-terminally 3FLAG-tagged pUL92 or pM92. MRC5 cells expressing tagged pUL92 (MRC5-UL92flag), tagged
pM92 (MRC5-M92flag), or the empty vector (MRC5-vector) were infected with ADinUL92 at an MOI of 0.001. At 14 dpi, cells were examined under a
fluorescence microscope for virus-driven GFP expression (C), and titers of cell free virus were determined by TCID50 assay in MRC5-UL92flag cells (D). The
detection limit of the TCID50 is indicated by a dashed line. (E) Cellular DNA of MRC5-UL92flag and MRC5-M92flag cells was isolated, and the presence of UL92
and M92 DNA in these cells was determined by PCR analysis using the primers listed in Table 1.
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(HSV-1) late gene trans factors (54, 55). Alternatively, pM92/
pM79 could play a more direct role in transcription. Herpesvirus
genes are transcribed by the cellular RNA polymerase II (RNAPII)
(56–59), a 12-subunit multicomponent enzyme that requires a
host of accessory scaffold and regulatory proteins for its activity.
The pM92/pM79 complex could play an essential role in the re-
cruitment or assembly of these components on viral late gene
promoters. Such a mechanism has been suggested for regulation
of late gene expression in both HSV and gammaherpesvirus (50,
60). Finally, the activity of pM92/pM79 complex could be re-
quired at the stage of posttranscriptional modification. It is clear
that accumulation of late transcripts was defective during mutant
virus infection, but it remains to be determined if this defect re-
sults from a failure in transcription or an alteration in mRNA
stability. HSV-1 endoribonuclease VHS-RNase is tightly regulated
by at least four other viral proteins in order to prevent it from
degrading viral mRNAs (61–64). Precedent for viral regulation of
viral mRNA accumulation also exists in HCMV, since viral pro-
tein IE2 can inhibit its own transcription by binding to the MIEP
promoter (18, 65). Thus, we cannot rule out the possibility that
during pM92-deficient mutant virus infection, a defect in RNA
trafficking, stability, or processing results in higher RNA turnover
rates.
Efforts are under way to gain a better mechanistic understand-
ing of the role of pM92 in late gene regulation. Identification of
cellular and viral factors that interact with pM92 is anticipated to
provide important insights into its function. Although pM79 is
one interaction partner of pM92, it is almost certain that many
additional partners exist. Furthermore, genetic and protein anal-
ysis to identify functional domains and structural elements of
pM92 will be invaluable to understand the mechanistic basis for its
activity and to determine additional functions that pM92 may
have. Finally, it is tempting to speculate that late gene expression
regulators such as pM92 and pM79 could play a role in the estab-
lishment of latency. Since both proteins are essential for the lytic
viral life cycle, regulation of their activity, and/or expression may
be a deciding factor for viral latency and reactivation.
In summary, we have identified pM92 as a novel late gene
regulator in MCMV lytic infection, shown its interaction with
another late gene regulator pM79, and demonstrated its con-
served function with its HCMV homolog, pUL92. pM92 repre-
sents a potential new target for therapeutic intervention in CMV
disease, and a gateway into studying a largely uncharted viral pro-
cess that is critical to the viral life cycle.
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